Exact Mass: 367.2022

Exact Mass Matches: 367.2022

Found 79 metabolites which its exact mass value is equals to given mass value 367.2022, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Bambuterol

3-[2-(tert-butylamino)-1-hydroxyethyl]-5-[(dimethylcarbamoyl)oxy]phenyl N,N-dimethylcarbamate

C18H29N3O5 (367.2107)


Bambuterol is only found in individuals that have used or taken this drug. It is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents

   

Dodeca-6,8,10-trienedioylcarnitine

3-[(11-carboxyundeca-6,8,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-6,8,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,8,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,8,10-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,8,10-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-4,7,10-trienedioylcarnitine

3-[(11-carboxyundeca-4,7,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-4,7,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,7,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,7,10-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,7,10-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine

3-[(11-carboxyundeca-2,6,8-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,6E,8E)-dodeca-2,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-5,7,9-trienedioylcarnitine

3-[(11-carboxyundeca-5,7,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-5,7,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,7,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,7,9-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,7,9-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-4,6,8-trienedioylcarnitine

3-[(11-carboxyundeca-4,6,8-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-4,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,6,8-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,6,8-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-3,6,9-trienedioylcarnitine

3-[(11-carboxyundeca-3,6,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-3,6,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,6,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,6,9-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,6,9-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,4-Dehydrocilostazol

6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2-dihydroquinolin-2-one

C20H25N5O2 (367.2008)


   
   

N(4)-Methylakuammidine

N(4)-Methylakuammidine

C22H27N2O3 (367.2022)


   
   

5F-Cumyl-PINACA

5F-Cumyl-PINACA

C22H26FN3O (367.206)


   

5F-CUMYL-P7AICA

5F-CUMYL-P7AICA

C22H26FN3O (367.206)


   

Oprea1_213167

Oprea1_213167

C23H29NOS (367.197)


   

12-hydroxy-4,19-dimethyl-(13betaH,14betaH)-14,19-dihydro-4,8-seco-crotalanane-8,11,15-trione|8,12-dihydroxy-4alpha,19-dimethyl-11,15-dioxo-(13betaH,14betaH)-14,19-dihydro-crotalananium betaine|Crosemperin|crosemperine

12-hydroxy-4,19-dimethyl-(13betaH,14betaH)-14,19-dihydro-4,8-seco-crotalanane-8,11,15-trione|8,12-dihydroxy-4alpha,19-dimethyl-11,15-dioxo-(13betaH,14betaH)-14,19-dihydro-crotalananium betaine|Crosemperin|crosemperine

C19H29NO6 (367.1995)


   

SIRT1 Activator 3

SIRT1 Activator 3

C20H25N5O2 (367.2008)


   

N-Desethylquinagolide

N-Desethylquinagolide

C18H29N3O3S (367.193)


   

CAY10591

2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

C20H25N5O2 (367.2008)


   
   

Bambuterol

3-[2-(tert-butylamino)-1-hydroxyethyl]-5-[(dimethylcarbamoyl)oxy]phenyl N,N-dimethylcarbamate

C18H29N3O5 (367.2107)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents

   

3,4-Dehydrocilostazol

3,4-Dehydro Cilostazol

C20H25N5O2 (367.2008)


   

N,N-BIS(2-HYDROXYETHYL)-N-METHYLDODECAN-1-AMINIUM BROMIDE

N,N-BIS(2-HYDROXYETHYL)-N-METHYLDODECAN-1-AMINIUM BROMIDE

C17H38BrNO2 (367.2086)


   

4-(3-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PROPYL)MORPHOLINE HYDROCHLORIDE

4-(3-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PROPYL)MORPHOLINE HYDROCHLORIDE

C19H31BClNO3 (367.2085)


   

3-(1-Trityl-1H-imidazol-4-yl)-propylamine

3-(1-Trityl-1H-imidazol-4-yl)-propylamine

C25H25N3 (367.2048)


   

butyl prop-2-enoate,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,prop-2-enenitrile

butyl prop-2-enoate,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,prop-2-enenitrile

C19H29NO6 (367.1995)


   

1,4-divinylbenzene,isocyanatomethylbenzene,styrene

1,4-divinylbenzene,isocyanatomethylbenzene,styrene

C26H25NO (367.1936)


   

ETHYL 2-AMINO-5-((7-ETHOXY-7-OXOHEPTYL)OXY)-4-METHOXYBENZOATE

ETHYL 2-AMINO-5-((7-ETHOXY-7-OXOHEPTYL)OXY)-4-METHOXYBENZOATE

C19H29NO6 (367.1995)


   

2,6-Difluoro-3,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2,6-Difluoro-3,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

C17H25B2F2NO4 (367.1938)


   
   
   

2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

C20H25N5O2 (367.2008)


D020536 - Enzyme Activators

   

16-Methoxytabersoninium(1+)

16-Methoxytabersoninium(1+)

C22H27N2O3+ (367.2022)


Conjugate acid of 16-methoxytabersonine arising from protonation of the endocyclic tertiary amino group.

   

(5Z,9S,11R,13E,15S)-15-hydroperoxy-9,11-epidioxyprosta-5,13-dien-1-oate

(5Z,9S,11R,13E,15S)-15-hydroperoxy-9,11-epidioxyprosta-5,13-dien-1-oate

C20H31O6- (367.2121)


   

2-N-acetylparomamine(2+)

2-N-acetylparomamine(2+)

C14H29N3O8+2 (367.1955)


   

Dodeca-5,7,9-trienedioylcarnitine

Dodeca-5,7,9-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-4,6,8-trienedioylcarnitine

Dodeca-4,6,8-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-3,6,9-trienedioylcarnitine

Dodeca-3,6,9-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-6,8,10-trienedioylcarnitine

Dodeca-6,8,10-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-4,7,10-trienedioylcarnitine

Dodeca-4,7,10-trienedioylcarnitine

C19H29NO6 (367.1995)


   

(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine

(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine

C19H29NO6 (367.1995)


   

2-[4-[(2R)-2-[(3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-dioxo-1-piperidinyl]acetic acid ethyl ester

2-[4-[(2R)-2-[(3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-dioxo-1-piperidinyl]acetic acid ethyl ester

C19H29NO6 (367.1995)


   

19-hydroxyprostaglandin H2(1-)

19-hydroxyprostaglandin H2(1-)

C20H31O6- (367.2121)


A prostaglandin carboxylic acid anion that is the conjugate base of 19-hydroxyprostaglandin H2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-6-methyl-5-(3-methylbutyl)pyrimidin-4(3H)-one

2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-6-methyl-5-(3-methylbutyl)pyrimidin-4(3H)-one

C20H25N5O2 (367.2008)


   

20-hydroxylipoxin A4(1-)

20-hydroxylipoxin A4(1-)

C20H31O6- (367.2121)


A lipoxin anion that is the conjugate base of 20-hydroxylipoxin A4 arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

20-hydroxylipoxin B4(1-)

20-hydroxylipoxin B4(1-)

C20H31O6- (367.2121)


A lipoxin anion that is the conjugate base of 20-hydroxy-lipoxin B4 arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

(3R,3aS,7R,7aS)-7-methyl-3-(2-naphthalenyl)-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one

(3R,3aS,7R,7aS)-7-methyl-3-(2-naphthalenyl)-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one

C26H25NO (367.1936)


   

11-dehydro-thromboxane B2(1-)

11-dehydro-thromboxane B2(1-)

C20H31O6- (367.2121)


A thromboxane anion that is the conjugate base of 11-dehydro-thromboxane B2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

20-hydroxy prostaglandin E2(1-)

20-hydroxy prostaglandin E2(1-)

C20H31O6- (367.2121)


   

1-[1-(Phenylmethyl)-4-piperidinyl]-3-(2-propan-2-ylphenyl)thiourea

1-[1-(Phenylmethyl)-4-piperidinyl]-3-(2-propan-2-ylphenyl)thiourea

C22H29N3S (367.2082)


   

(5Z,13E,15S)-9alpha,11alpha-epoxy-15,19-dihydroxythromboxa-5,13-dien-1-oate

(5Z,13E,15S)-9alpha,11alpha-epoxy-15,19-dihydroxythromboxa-5,13-dien-1-oate

C20H31O6- (367.2121)


   

(5Z,13E,15S)-9alpha,11alpha-epoxy-15,18-dihydroxythromboxa-5,13-dien-1-oate

(5Z,13E,15S)-9alpha,11alpha-epoxy-15,18-dihydroxythromboxa-5,13-dien-1-oate

C20H31O6- (367.2121)


   

(5Z,13E,15S)-11alpha,15,19-trihydroxy-6,9alpha-epoxyprosta-5,13-dien-1-oate

(5Z,13E,15S)-11alpha,15,19-trihydroxy-6,9alpha-epoxyprosta-5,13-dien-1-oate

C20H31O6- (367.2121)


   

(5Z,8S,9E,11Z,13E,15S)-8,15-bis(hydroperoxy)icosa-5,9,11,13-tetraenoate

(5Z,8S,9E,11Z,13E,15S)-8,15-bis(hydroperoxy)icosa-5,9,11,13-tetraenoate

C20H31O6- (367.2121)


   

(5S,6E,8Z,11Z,13E,15S)-5,15-bis(hydroperoxy)icosa-6,8,11,13-tetraenoate

(5S,6E,8Z,11Z,13E,15S)-5,15-bis(hydroperoxy)icosa-6,8,11,13-tetraenoate

C20H31O6- (367.2121)


   

(15S)-15-hydroperoxy-prostaglandin E2

(15S)-15-hydroperoxy-prostaglandin E2

C20H31O6- (367.2121)


   

(5Z,8Z,10E,12E,14R,15S)-14,15-bis(hydroperoxy)icosa-5,8,10,12-tetraenoate

(5Z,8Z,10E,12E,14R,15S)-14,15-bis(hydroperoxy)icosa-5,8,10,12-tetraenoate

C20H31O6- (367.2121)


   

(5S,6R,7E,9E,11Z,13E,15S)-15-hydroperoxy-5,6-dihydroxyicosa-7,9,11,13-tetraenoate

(5S,6R,7E,9E,11Z,13E,15S)-15-hydroperoxy-5,6-dihydroxyicosa-7,9,11,13-tetraenoate

C20H31O6- (367.2121)


   

3-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazol-3-ium

3-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazol-3-ium

C22H27N2O3+ (367.2022)


   

N-[9-(2-carboxyethyl)-6-(ethylamino)-2,7-dimethyl-3H-xanthen-3-ylidene]ethanaminium

N-[9-(2-carboxyethyl)-6-(ethylamino)-2,7-dimethyl-3H-xanthen-3-ylidene]ethanaminium

C22H27N2O3+ (367.2022)


   

(13E,15S)-11alpha,15-dihydroxy-6,9-dioxoprost-13-en-1-oate

(13E,15S)-11alpha,15-dihydroxy-6,9-dioxoprost-13-en-1-oate

C20H31O6- (367.2121)


   

(5S,6Z,8E,10E,12R,14Z)-5,12,20,20-tetrahydroxyicosa-6,8,10,14-tetraenoate

(5S,6Z,8E,10E,12R,14Z)-5,12,20,20-tetrahydroxyicosa-6,8,10,14-tetraenoate

C20H31O6- (367.2121)


   

2-[[(E)-2-acetamido-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-acetamido-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C15H32N2O6P+ (367.1998)


   

prostaglandin G2(1-)

prostaglandin G2(1-)

C20H31O6 (367.2121)


A prostaglandin carboxylic acid anion that is the conjugate base of prostaglandin G2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

19-hydroxythromboxane A2(1-)

19-hydroxythromboxane A2(1-)

C20H31O6 (367.2121)


A thromboxane anion that is the conjugate base of 19-hydroxythromboxane A2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

18-hydroxythromboxane A2(1-)

18-hydroxythromboxane A2(1-)

C20H31O6 (367.2121)


A thromboxane anion that is the conjugate base of 18-hydroxythromboxane A2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoate

(5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoate

C20H31O6 (367.2121)


A bis(hydroperoxy)icosatetraenoate that is the conjugate base of (5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

6-oxoprostaglandin E1(1-)

6-oxoprostaglandin E1(1-)

C20H31O6 (367.2121)


A prostaglandin carboxylic acid anion that is the conjugate base of 6-oxoprostaglandin E1, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

8(S),15(S)-DiHPETE(1-)

8(S),15(S)-DiHPETE(1-)

C20H31O6 (367.2121)


An icosanoid anion that is the conjugate base of 8(S),15(S)-DiHPETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

14(R),15(S)-DiHPETE(1-)

14(R),15(S)-DiHPETE(1-)

C20H31O6 (367.2121)


A bis(hydroperoxy)icosatetraenoate that is the conjugate base of 14(R),15(S)-DiHPETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoate

(5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoate

C20H31O6 (367.2121)


An hydroperoxy(hydroxy)icosatetraenoate that is the conjugate base of (5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoic acid; major species at pH 7.3.

   

19-hydroxyprostaglandin I2(1-)

19-hydroxyprostaglandin I2(1-)

C20H31O6 (367.2121)


A prostaglandin carboxylic acid anion that is the conjugate base of 19-hydroxyprostaglandin I2, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

C19H29NO6 (367.1995)


   

6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

C19H29NO6 (367.1995)


   
   

(2e)-n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

(2e)-n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

C19H29NO6 (367.1995)


   

n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dec-2-enimidic acid

n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dec-2-enimidic acid

C19H29NO6 (367.1995)


   

(1r,4r,5s,6r,10z)-6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

(1r,4r,5s,6r,10z)-6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

C19H29NO6 (367.1995)


   

n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

C19H29NO6 (367.1995)